Baird Financial Group, Inc. Avidity Biosciences, Inc. Transaction History
Baird Financial Group, Inc.
- $50.2 Billion
- Q3 2024
A detailed history of Baird Financial Group, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 23,891 shares of RNA stock, worth $788,880. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23,891
Previous 32,803
27.17%
Holding current value
$788,880
Previous $1.34 Million
18.13%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding RNA
# of Institutions
252Shares Held
110MCall Options Held
197KPut Options Held
184K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$351 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$311 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$285 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$269 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$268 Million0.04% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.72B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...